Assyro AI

Purple Book product · Biosimilar 351(k)

Ziextenzo

pegfilgrastim-bmez

351(k) BiosimilarBLA 761045RxLicensed Sandoz Inc.

Nov 04, 2019

Approved

Biosimilar 351(k)

License type

Rx

Marketing

1

Listed patents

Ziextenzo (pegfilgrastim-bmez) is a Biosimilar 351(k) referencing pegfilgrastim, licensed under a 351(k) BLA in 2019 and marketed by Sandoz Inc.. The Purple Book lists 1 published patent for this product.

Sourced from the FDA Purple Book · verified Jul 02, 2026

Key dates

  1. Approval

    Approval date of this BLA submission.

    Nov 04, 2019

    6 yr 10 mo ago

  2. Today

Pharmaceutical detail

Strength

6MG/0.6ML

Dosage form

Injection

Route

Subcutaneous

Presentation

Pre-Filled Syringe

Center

CDER

License number

2003

Product number

001

Submission type

Original

Supplement number

Not listed

Change type

Not listed

Reference product family

View full family

Biosimilar of pegfilgrastim (Neulasta)

Patent list (1)

Patents published in the FDA Purple Book Patent List for this product, with expiration date and source link.
PatentExpiresInSource
9,856,287Jun 21, 2030in 4 yrFDA

Source provenance

Source kind · Advanced Search
Checked Jul 02, 2026
  • advanced-searchAdvanced Search · Jul 02, 2026
  • monthly-downloadMonthly download · Jul 02, 2026

Change history

  • v4Jul 02, 2026
  • v3Jul 02, 2026
  • v2Jul 02, 2026

Frequently asked questions

When do Ziextenzo's patents expire?

The FDA Purple Book lists 1 published patent for Ziextenzo, with the last listed patent expiring Jun 21, 2030. Every patent below links to its FDA source record so you can verify the expiration date.

Is Ziextenzo a biosimilar?

Yes. Ziextenzo is a Biosimilar 351(k) referencing pegfilgrastim, licensed under a 351(k) BLA.

Is Ziextenzo interchangeable?

Ziextenzo is a 351(k) biosimilar but does not carry an interchangeability designation in the Purple Book, so pharmacy-level substitution depends on state law.

What is Ziextenzo's BLA number?

Ziextenzo is licensed under BLA 761045, held by Sandoz Inc..

When was Ziextenzo approved by the FDA?

Ziextenzo was approved by the FDA on Nov 04, 2019.

Related FDA reference tools

Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.